Please login to the form below

Not currently logged in
Email:
Password:

Krystexxa

This page shows the latest Krystexxa news and features for those working in and with pharma, biotech and healthcare.

FDA approves Horizon's thyroid eye disease drug ahead of schedule

FDA approves Horizon's thyroid eye disease drug ahead of schedule

Horizon raised its revenue expectations for Krystexxa (pegloticase injection), a gout therapy that is already on the market, by the same amount.

Latest news

  • Horizon swoops on Raptor to add rare disease products Horizon swoops on Raptor to add rare disease products

    In January it bought Crealta in a deal valued at $510m that brought in Krystexxa (pegloticase), an FDA-approved drug for chronic refractory gout.

  • AZ moves a step closer to gout drug approval in US AZ moves a step closer to gout drug approval in US

    Another recent entrant into the market - Savient Pharmaceuticals - was unable to make headway with its Krystexxa (pegloticase) therapy and was forced to file for bankruptcy in 2013.

  • AZ files gout drug lesinurad in Europe AZ files gout drug lesinurad in Europe

    Another recent entrant into the gout market - Savient Pharmaceuticals - was forced to file for bankruptcy in 2013 after poor sales of its gout therapy Krystexxa (pegloticase).

  • Phase III data back AZ's gout drug Phase III data back AZ's gout drug

    On the other hand, another recent entrant into the market - Savient Pharmaceuticals - was forced to file for bankruptcy last year on lacklustre sales of its gout therapy Krystexxa (pegloticase).

  • Good news for AZ on gout candidate lesinurad Good news for AZ on gout candidate lesinurad

    Another company with high expectations - Savient Pharma - was forced to file for bankruptcy protection in October after sales of its gout treatment Krystexxa (pegloticase) remained stubbornly low despite being launched in ... 2011. Krystexxa's poor

More from news
Approximately 2 fully matching, plus 13 partially matching documents found.

Latest Intelligence

  • Deal Watch December 2015 Deal Watch December 2015

    575. Crealta. Horizon. Acquisition - company. Krystexxa marketed for treatment of chronic refractory gout.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
claire@dovetailstrategies.com

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics